AgingResearch.NewsJoin free

NERBIO

Company

NERBIO develops one asset, in phase 3 (F16IL2 in soft tissue sarcoma). Mostly protein or enzyme acting on inflammation, IL2RA and IL2RB.

1
Asset
Furthest stage
Phase 3
10
Trials
0
Signals

Pipeline

1

  • F16IL2

    Antibody-cytokine fusion protein targeting the A1 domain of tenascin-C coupled with interleukin-2.

    Phase 3, Protein or enzyme, Inflammation, IL2RA, soft tissue sarcoma, leiomyosarcoma (Phase 2)

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

1

In the full profile

  • Evidence behind the mechanisms5
  • Trials10
  • Similar companies6

Intelligence